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Background: The purpose of this study was to evaluate the efficacy and safety of carbohydrate-
derived fulvic acid (CHD-FA) in the treatment of eczema in patients two years and older.
Methods: In this single-center, double-blind, placebo-controlled, parallel-group comparative 
study, 36 volunteers with predetermined eczema were randomly assigned to receive either the 
study drug or placebo twice daily for four weeks.
Results: All safety parameters remained within normal limits, with no significant differences 
in either group. Significant differences were observed for both severity and erythema in the 
placebo and CHD-FA treated groups, and a significant difference was observed for scaling in 
the placebo-treated group. With regard to the investigator assessment of global response to 
treatment, a significant improvement was observed in the CHD-FA group when compared with 
the placebo group. A statistically significant decrease in visual analog scale score was observed 
in both groups, when comparing the baseline with the final results.
Conclusion: CHD-FA was well tolerated, with no difference in reported side effects other than 
a short-lived burning sensation on application. CHD-FA significantly improved some aspects of 
eczema. Investigator assessment of global response to treatment with CHD-FA was significantly 
better than that with emollient therapy alone. The results of this small exploratory study suggest 
that CHD-FA warrants further investigation in the treatment of eczema.
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Introduction
Fulvic acid is one of the components of the so-called humic substances, which are formed 
naturally during the decay of plant and animal residues.1 These substances can be divided 
into humic acid, fulvic acid, and humin on the basis of solubility in water as a function 
of pH.2 Fulvic acid is the fraction that is soluble in water under all pH conditions and 
is generally lower in molecular size, weight, and color intensity when compared with 
the humic acids.2 Oxifulvic acid has been shown in vitro to have antimicrobial activity3 
and to suppress superoxide production by neutrophils. Topical application of oxifulvic 
acid to laboratory mice has demonstrated clear anti-inflammatory properties.2 Heavy 
metal-free, carbohydrate-derived fulvic acid (CHD-FA) has been tested in pilot studies, 
and found to have similar properties when compared with oxifulvic acid.4 Traditionally, 
CHD-FA has been used to treat a variety of diseases, including skin conditions, although 
the exact mechanism of action in eczema is not clear due to its complex mixture of acids 
with different activities and properties, including antimicrobial effects.
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The purpose of this study was to evaluate the efficacy and 
safety of fulvic acid in the treatment of eczema in patients 
aged two years and older. Eczema is often a recurrent and 
difficult disease to treat, with topical glucocorticoids used 
to treat flares and normal emollients used for maintenance 
therapy. In chronic conditions, topical calcineurin antagonists 
(eg, pemicrolimus or tacrolimus) are used or may even be 
supplemented with systemic immunosuppressive therapy 
in severe cases.
The importance of pH is also recognized in skin diseases. 
Some diseases or stages are associated with different pH 
levels. An increase in skin pH may be due to atopic and 
seborrheic dermatitis, especially acute lesions that are ery-
thematous with exudates and crusts, while chronic atopic 
dermatitis lesions with lichenification and scaling are only 
slightly more alkaline than normal skin.5 In many of these 
diseases, the pathogenesis of alkalinization is not clear, 
but the higher pH likely predisposes the skin to secondary 
infections.6
Fulvic acid, with its known anti-inflammatory proper-
ties and good safety profile, has the added benefit of being 
an acid. Reducing the pH of the skin also relieves the itch 
during eczema. In this study, 3.5% CHD-FA in an emollient 
(buffered to pH 4.8) was compared with an acidic (pH 4.8) 
emollient to establish the anti-inflammatory properties of 
CHD-FA in patients with eczema.
Materials and methods
In this single-center, double-blind, placebo-controlled, 
parallel-group comparative study, 36 volunteers with known 
eczema were randomly assigned to receive either the study 
drug or a placebo emollient applied twice daily for four 
weeks. Treatment period observations and measurements 
included improvement in visual analog scale score and 
investigator global assessment. Blood samples were taken 
at baseline and again at the end of the study, and included a 
full blood count, and liver and kidney function tests. Clinical 
examination, electrocardiogram, documentation of adverse 
events, and laboratory investigations were also performed 
to confirm safety.
Healthy males and females over the age of two years 
were eligible for inclusion in this study. Female patients 
were required to use reliable contraception if they were 
of childbearing age. A previous diagnosis of eczema 
was required. Patients were required to give their written 
informed consent to participate. Exclusion criteria included 
renal impairment, liver disease, abnormal liver function 
tests, hematological abnormalities, any autoimmune disease 
other than eczema, pregnancy, lactation, participation in 
any other clinical trial within the previous month, clinical 
signs of infection, use of concomitant medication, sys-
temic corticosteroids, phototherapy/immune suppression/
antihistamines, topical tacrolimus/pemicrolimus within the 
previous four weeks, or topical corticosteroids within the 
previous four days.
A CHD-FA 3.5% or placebo (pH 4.8) emollient was 
applied twice daily to affected areas as well as Epizone A® 
emollient buffered with acetic acid as needed.
Statistical analysis
Blood parameters, visual analog scale score, and investiga-
tor assessment of disease severity were analyzed using the 
  Wilcoxon Rank test at a 95% confidence level. The investiga-
tor assessment of global response to treatment was analyzed 
using the Mann-Whitney U test for nonparametric data. All 
analysis was done using Graphpad Prism 4.0.
Results
Thirty-six patients completed the trial. Two patients used 
concomitant medication during the study period and were 
excluded from the results. No significant differences in kidney 
function tests were observed between the treatment groups. 
Table 1 Investigator assessment of severity of disease
Placebo (n = 18) CHD-FA (n = 18)
Base ±SD Final ±SD Base ±SD Final ±SD
Severity 2.278 0.826 1.222* 0.732 1.833 0.514 0.8331 0.707
Erythema 2.056 0.998 1.056** 0.873 1.176 0.728 0.2352 0.437
Vesiculation 0.333 0.686 0.056 0.236 0.353 0.493 0.000 0.000
Fissuring 0.056 0.236 0.056 0.236 0.000 0.000 0.000 0.000
Scaling 0.500 0.707 0.056*** 0.236 0.176 0.529 0.059 0.243
Notes: *P = 0.0009; **P = 0.0059; ***P = 0.0313; 1P , 0.0001; 2P = 0.0002 (all by Wilcoxon Signed Rank test). (0 = absent, 1 = mild, 2 = moderate, 3 = moderately severe, 
4 = severe.)
Abbreviations: CHD-FA, carbohydrate-derived fulvic acid; SD, standard deviation.
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Table 2 Investigator assessment of global response to treatment
Scale response (0–6)
Average ±SD
Placebo (n = 18) 2.94 1.11
CHD-FA (n = 18) 1.77* 1.00
Notes: * P  ,  0.05  (by  Mann-Whitney  U  test).  0  =  completely  clear 
except  for  possible  residual  hyperpigmentation,  1  =  almost  clear,  very 
significant  clearance  (about  90%),  2  =  marked  improvement/significant 
improvement (about 75%), 3 = moderate improvement (about 50%), 4 = slight 
improvement  (about  25%),  but  significant  disease  remaining,  5  =  no  change 
(moderate to severe disease), 6 = worse. 
Abbreviations:  CHD-FA,  carbohydrate-derived  fulvic  acid;  SD,  standard 
deviation.
Table 3 Visual analog scale results.
Percentage scale response (0–100 mm)
Base ±SD Final ±SD
Placebo (n = 18) 62.81 20.89 34.72* 26.81
CHD-FA (n = 17) 69.50 14.65 29.60** 19.71
Notes: *P = 0.003; **P = 0.0005 (both Wilcoxon Signed Rank test). 
Abbreviations:  CHD-FA,  carbohydrate-derived  fulvic  acid;  SD,  standard 
deviation.
With regard to liver function tests, a statistically significant 
difference was observed for aspartate transaminase, although 
values remained within normal limits, as did the rest of the 
laboratory parameters for the liver. All safety parameters in 
the full blood count also remained within normal limits. The 
only side effect reported was a short-lived burning sensation 
after application of treatment.
Efficacy
Severity, erythema, vesiculation, fissuring, and scaling were 
monitored by the investigators during the study. Significant 
differences were observed for both severity and erythema 
in the placebo-treated and CHD-FA-treated groups, as 
well as a significant difference in scaling in the placebo-
treated group. The rest of the parameters remained within 
normal limits (Table 1). Investigator assessment of global 
response to treatment was performed using the following 
seven-point scale: 0 = completely clear, 1 = almost clear 
(about 90%), 2 = marked improvement (75%), 3 = moder-
ate improvement (50%), 4 = slight improvement (25%), 
5 = no change (moderate to severe disease) and 6 = worse.7 
A significant improvement in global response to treatment 
was observed in the CHD-FA group when compared with 
the placebo group (Table 2). A statistically significant 
decrease in scores on the visual analog scale was observed 
in both groups, when comparing baseline values with the 
final results (Table 3).
Discussion
All blood safety parameters remained within acceptable 
ranges. CHD-FA is a combination of weak acids buffered 
to pH 4.8, which could account for the burning sensation 
on application. Extensive clinical safety parameters have 
already been established for systemically administered 
CHD-FA (unpublished data). Our trial has further estab-
lished that changing the route of administration from 
systemic to topical does not affect the safety profile of the 
product.
A standard five-point severity grading scale (0 = absent 
to 4 = severe) has been used to evaluate five characteristics 
of eczema, ie, severity, erythema, vesiculation, fissuring, and 
scaling.8 Both treatment groups demonstrated significant 
improvements in some of the characteristics tested, which 
is not uncommon in eczema trials, whereby application 
of an emollient (pH-adjusted) may improve the condition. 
According to the investigator assessment of global response 
to treatment, the group treated with CHD-FA showed a 
significant improvement when compared with the placebo 
group, thus demonstrating the anti-inflammatory properties 
of CHD-FA, leading to a significant overall improvement of 
the condition (Figure 1).
The severity of eczema was evaluated by the patients 
using a visual analog scale, defined on a 10 cm line where 0 
refers to no eczema and 10 refers to the most severe eczema 
experienced by the patient.7 A significant decrease was 
observed for both groups, indicating that both treatments 
alleviated patient perception of eczema.
Conclusion
In this trial, CHD-FA significantly improved some features 
of eczema, in particular, overall severity and erythema. 
Investigator assessment of global response to treatment 
with CHD-FA was significantly better than that with emol-
lient therapy only. CHD-FA was well tolerated, with no 
difference in reported side effects, other than a short-lived 
Pre-treatment Post-treatment
Figure 1 Photograph of patient before and after treatment.
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burning   sensation on application. This small exploratory 
study   suggests that further investigation of the clinical use 
of CHD-FA in eczema is warranted.
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